CYDY — CytoDyn Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1175680 ·
Last close
$0.19
Market Cap
$260.25M
52W High
$0.37
52W Low
$0.19
ADV30
2,046,013
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Feb 2026 | 0 | — | -6,303,000 | -4,690,000 | 18,497,000 | 15,655,000 | 122,784,000 |
| Nov 2025 | 0 | — | -5,101,000 | -22,607,000 | 8,935,000 | 4,982,000 | 128,683,000 |
| May 2025 | 0 | — | -5,066,000 | -5,956,000 | 18,047,000 | 11,903,000 | 114,089,000 |
| Feb 2025 | 0 | — | -4,003,000 | -4,758,000 | 21,191,000 | 16,400,000 | 114,170,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,488,000
Investing CF
$0
Financing CF
$17,379,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.02
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-920,623,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-34,486,000
Pretax Income TTM
$-38,011,000
Interest Exp TTM
$3,525,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| May 2025 | 0 | 9,661,000 | 3,745,000 | 18,047,000 | 114,089,000 | — | -8,765,000 |
| May 2024 | 0 | -18,058,000 | -49,841,000 | 11,136,000 | 127,894,000 | — | -10,982,000 |
| May 2023 | 0 | -40,576,000 | -79,824,000 | 11,292,000 | 120,793,000 | — | -25,110,000 |
| May 2022 | 266,000 | -145,404,000 | -210,820,000 | 29,185,000 | 123,583,000 | — | -77,723,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.18
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELDN | Eledon Pharmaceuticals, Inc. | $260.89M | $3.38 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $261.05M | $1.94 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $262.93M | $0.16 | — |
| TRDA | Entrada Therapeutics, Inc. | $263.59M | $6.79 | — |
| FHTX | Foghorn Therapeutics Inc. | $265.97M | $4.53 | — |
News headlines (Yahoo Finance, 1h cache)
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
2026-06-11 12:30 · Yahoo
CytoDyn to Present at the LD Micro Invitational XVI
2026-05-15 12:30 · Yahoo
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
2026-04-27 12:30 · Yahoo
CytoDyn to Host Investor Webcast
2026-04-23 12:30 · Yahoo
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
2026-04-22 12:30 · Yahoo
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
2026-04-21 20:10 · Yahoo
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
2026-04-20 12:30 · Yahoo
CytoDyn to Present at the AACR Annual Meeting 2026
2026-04-14 12:30 · Yahoo
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
2026-03-24 12:30 · Yahoo
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
2026-03-05 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.